according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

SECTION 1. IDENTIFICATION

Product name : Milbemycin Oxime / Lufenuron Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

:

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Skin sensitization : Category 1

Reproductive toxicity : Category 1B

Specific target organ toxicity

- repeated exposure

: Category 1 (Central nervous system)

Specific target organ toxicity

- repeated exposure (Oral)

Category 1 (Central nervous system, Lungs, Liver, Stomach)

GHS label elements

Hazard pictograms





Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.

H360D May damage the unborn child.

H372 Causes damage to organs (Central nervous system)

through prolonged or repeated exposure.

H372 Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure

if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/04/2023

 2.7
 09/30/2023
 6365226-00009
 Date of first issue: 09/21/2020

P260 Do not breathe dust, fume, gas, mist, vapors or spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing must not be allowed out of

the workplace.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P308 + P313 IF exposed or concerned: Get medical attention. P333 + P313 If skin irritation or rash occurs: Get medical attention.

P363 Wash contaminated clothing before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Lufenuron (ISO)	103055-07-8	30.7
Polyethylene glycol	25322-68-3	29.1
Cellulose	9004-34-6	16
Starch	9005-25-8	5
Milbemycin Oxime	129496-10-2	1.6

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water. May cause an allergic skin reaction.

Most important symptoms and effects, both acute and

May damage the unborn child.

and effects, both acute and delayed

Causes damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

ngnung

Carbon oxides
Nitrogen oxides (NOx)

Hazardous combustion products

Metal oxides

Specific extinguishing methods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.
Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapors or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Lufenuron (ISO)	103055-07-8	TWA	OEB 3 (>= 10 < 100 μg/m3)	Internal
Polyethylene glycol	25322-68-3	TWA (aero- sol)	10 mg/m ³	US WEEL
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/04/2023

 2.7
 09/30/2023
 6365226-00009
 Date of first issue: 09/21/2020

		TWA (Respirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Milbemycin Oxime	129496-10-2	TWA	0.1 mg/m3 (OEB2)	Internal

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid

Color : brown

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

Autoignition temperature

: Not applicable

No data available

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

No data available Decomposition temperature

Viscosity

Viscosity, kinematic Not applicable

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Can react with strong oxidizing agents.

Possibility of hazardous reac- :

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Acute toxicity estimate: 75 mg/l Acute inhalation toxicity

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute toxicity estimate: > 5,000 mg/kg Acute dermal toxicity

Method: Calculation method

Components:

Lufenuron (ISO):

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): 2,350 mg/m³

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Polyethylene glycol:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: Based on data from similar materials

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Milbemycin Oxime:

Acute oral toxicity : LD50 (Rat): 532 - 863 mg/kg

LD50 (Mouse): 722 - 946 mg/kg

Acute inhalation toxicity : LC50 (Rat): 1,200 mg/m³

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Lufenuron (ISO):

Species : Rabbit
Method : Draize Test
Result : No skin irritation

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Polyethylene glycol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Milbemycin Oxime:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Lufenuron (ISO):

Species : Rabbit

Result : No eye irritation Method : Draize Test

Polyethylene glycol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

Starch:

Species : Rabbit

Result : No eye irritation

Milbemycin Oxime:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Not classified based on available information.

Components:

Lufenuron (ISO):

Test Type : Maximization Test

Species : Guinea pig

Assessment : May cause sensitization by skin contact.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Result : Sensitizer

Polyethylene glycol:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Starch:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Milbemycin Oxime:

Routes of exposure : Skin contact Species : Guinea pig Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Lufenuron (ISO):

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Mouse Lymphoma Test system: Chinese hamster cells

Result: negative

Test Type: Cytogenetic assay

Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Result: negative

Test Type: Unscheduled DNA synthesis test (UDS) in testicu-

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

lar cells Species: Rat Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Polyethylene glycol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Milbemycin Oxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Lufenuron (ISO):

Species : Rat
Application Route : Ingestion
Exposure time : 18 month(s)
Result : negative

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child.

Components:

Lufenuron (ISO):

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: NOAEL: 8.3 mg/kg wet weight Early Embryonic Development: NOAEL: 20.9 mg/kg body

weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: NOAEL: 500 mg/kg body weight Developmental Toxicity: NOAEL: 1,000 mg/kg body weight

Symptoms: No adverse effects.

Remarks: No significant adverse effects were reported

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

General Toxicity Maternal: NOAEL: 20.9 mg/kg body weight

Embryo-fetal toxicity.: 8.3 mg/kg body weight

Result: Fetal abnormalities.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

Cellulose:

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Milbemycin Oxime:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Dog

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

Test Type: Embryo-fetal development

Species: Dog

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

Components:

Lufenuron (ISO):

Assessment : The substance or mixture is not classified as specific target

organ toxicant, single exposure.

STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure. Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.

Components:

Lufenuron (ISO):

Routes of exposure : Oral

Target Organs : Central nervous system, Lungs, Liver, Stomach

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Milbemycin Oxime:

Routes of exposure : Ingestion

Target Organs : Central nervous system

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Lufenuron (ISO):

Species : Rat

NOAEL : 5.34 mg/kg Application Route : oral (feed) Exposure time : 4 Months

Target Organs : Central nervous system, digestive system

Symptoms : central nervous system effects

Species : Rat

NOAEL : 1.93 mg/kg Application Route : oral (feed)

Exposure time : 2 y

Symptoms : central nervous system effects, Convulsions

Species : Mouse
NOAEL : 2.12 mg/kg
Application Route : oral (feed)
Exposure time : 18 Months

Target Organs : Central nervous system, Liver, Prostate Symptoms : central nervous system effects, Convulsions

Species : Dog NOAEL : 7.02 mg/kg Application Route : oral (feed)

Exposure time : 1 y

Target Organs : Central nervous system, Liver, Lungs Symptoms : Convulsions, Fatality, Irregularities

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Milbemycin Oxime:

Species : Rat

NOAEL : 3 mg/kg

LOAEL : 15 mg/kg

Application Route : Ingestion

Exposure time : 90 Days

Symptoms : Liver disorders, Blood disorders

Species : Dog
LOAEL : 8.6 mg/kg
Application Route : Ingestion
Exposure time : 3 Days
Symptoms : Tremors

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Lufenuron (ISO):

General Information : Remarks: May be harmful if swallowed.

May cause neurotoxic effects.

Milbemycin Oxime:

Ingestion : Symptoms: Salivation, Convulsions, Diarrhea, Weakness,

Vomiting, Tremors, Coma

Remarks: Based on Animal Evidence

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lufenuron (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 73,100 μg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): > 29,000 μg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 370 µg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0.042 µg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic : EC50 (Raphidocelis subcapitata (freshwater green alga)): 209

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

plants µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Scenedesmus subspicatus): 17 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Oncorhynchus mykiss (rainbow trout)): 80 µg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

NOEC (Oncorhynchus mykiss (rainbow trout)): 20 μg/l

Exposure time: 359 d

Method: OECD Test Guideline 229

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 8.38 µg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

NOEC (Daphnia magna (Water flea)): 90 μg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

NOEC (Chironomus riparius (harlequin fly)): 2 µg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Polyethylene glycol:

Toxicity to fish : LC50 (Poecilia reticulata (guppy)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Milbemycin Oxime:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.16 μg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.03 μg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

: EC50: > 87 μg/l

Exposure time: 72 h

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.01 µg/l

16/21

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

Persistence and degradability

Components:

Polyethylene glycol:

Biodegradability Result: rapidly degradable

Remarks: Based on data from similar materials

Cellulose:

Biodegradability Result: Readily biodegradable.

Bioaccumulative potential

Components:

Lufenuron (ISO):

Bioaccumulation Species: Lepomis macrochirus (Bluegill sunfish)

> Bioconcentration factor (BCF): 28 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 5.12

Polyethylene glycol:

Partition coefficient: n-

octanol/water

log Pow: < 3

Milbemycin Oxime:

Bioaccumulation Bioconcentration factor (BCF): 440

Partition coefficient: n-

octanol/water

log Pow: 7

Mobility in soil

Components:

Lufenuron (ISO):

Distribution among environ-

log Koc: 5.38

mental compartments Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 09/30/2023 6365226-00009 Date of first issue: 09/21/2020 2.7

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number UN 3077

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Milbemycin Oxime, Lufenuron (ISO))

Class 9 Packing group Ш Labels 9 Environmentally hazardous yes

IATA-DGR

UN 3077 UN/ID No.

Proper shipping name Environmentally hazardous substance, solid, n.o.s.

(Milbemycin Oxime, Lufenuron (ISO))

Class Packing group Ш

Labels Miscellaneous

Packing instruction (cargo 956

aircraft)

Packing instruction (passen-

ger aircraft)

Environmentally hazardous

IMDG-Code

UN number **UN 3077**

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

956

yes

(Milbemycin Oxime, Lufenuron (ISO))

Class 9 Ш Packing group Labels 9 **EmS Code** F-A, S-F Marine pollutant ves

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number **UN 3077**

Proper shipping name Environmentally hazardous substance, solid, n.o.s.

(Milbemycin Oxime, Lufenuron (ISO))

Class 9 Packing group Ш CLASS 9 Labels **ERG Code** 171

Marine pollutant yes(Milbemycin Oxime, Lufenuron (ISO))

Remarks Above applies only to containers over 119 gallons or 450

Above applies only to containers over 119 gallons or 450

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

liters.

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Respiratory or skin sensitization

Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Lufenuron (ISO)103055-07-8Polyethylene glycol25322-68-3Cellulose9004-34-6D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate64044-51-5Starch9005-25-8

California Permissible Exposure Limits for Chemical Contaminants

 Cellulose
 9004-34-6

 Starch
 9005-25-8

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the OSHA Hazard Communication Standard




Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.7 09/30/2023 6365226-00009 Date of first issue: 09/21/2020

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

US WEEL : USA. Workplace Environmental Exposure Levels (WEEL)

ACGIH / TWA : 8-hour, time-weighted average

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average

US WEEL / TWA : 8-hr TWA

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials: bw - Body weight: CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-

according to the OSHA Hazard Communication Standard



Milbemycin Oxime / Lufenuron Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/04/2023

 2.7
 09/30/2023
 6365226-00009
 Date of first issue: 09/21/2020

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8